- Previous Close
0.950 - Open
1.220 - Bid 1.000 x --
- Ask 1.130 x --
- Day's Range
1.000 - 1.220 - 52 Week Range
0.920 - 1.950 - Volume
27,000 - Avg. Volume
283,669 - Market Cap (intraday)
1.092B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin's lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer's disease and sjogren's syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus. In addition, the company develops SM06, a humanised Anti-CD22, which is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren's syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin's lymphoma and autoimmune diseases. SinoMab BioScience Limited was incorporated in 2001 and is based in Tai Po, Hong Kong.
www.sinomab.comRecent News: 3681.HK
View MorePerformance Overview: 3681.HK
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3681.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3681.HK
View MoreValuation Measures
Market Cap
1.04B
Enterprise Value
1.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
461.35
Price/Book (mrq)
3.53
Enterprise Value/Revenue
622.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.63%
Return on Equity (ttm)
-58.45%
Revenue (ttm)
2M
Net Income Avi to Common (ttm)
-199.64M
Diluted EPS (ttm)
-0.200
Balance Sheet and Cash Flow
Total Cash (mrq)
194.86M
Total Debt/Equity (mrq)
173.11%
Levered Free Cash Flow (ttm)
-208.5M